Sobi sold!Thanks for the ride! My guess is that there is not much more that I can get out of this one.
Swedish Orphan Biovitrum AB
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.15 USD
51.72 M USD
3.06 B USD
179.73 M
About Swedish Orphan Biovitrum AB
Sector
Industry
CEO
Guido Oelkers
Website
Headquarters
Solna
Founded
2001
IPO date
Sep 15, 2006
Identifiers
2
ISIN SE0000872095
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. It operates through the Haematology, Immunology, and Specialty Care segments. The Haemotology segment focuses on haemophilia medicines Elocta and Alprolix. The immunology segment offers treatment for serious, disabling, and life-threatening diseases. The Specialty Care segment specializes in the treatment of genetic and metabolic diseases. The company was founded in 2001 and is headquartered in Solna, Sweden.
Related stocks
Long
Short
Swedish Orphan Biovitrum (SOBI.ST) breakout from consolidationSanofi's bid yesterday for SOBI's partner Bioverativ at a 60%+ premium is highly supportive for SOBI's valuation. Strong future in haemophilia products Eloctate and Alprolix. As the European territory (SOBI territory) launches were two years later than the US, SOBI's sales are at an earlier stage, a
Long
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
MEUH
Amundi Core Stoxx Europe 600 -UCITS ETF HEDGED- CapitalisationWeight
0.07%
Market value
13.99 M
USD
STXH
Amundi Index Solutions SICAV - Amundi Core Stoxx Europe 600 UCITS ETF Monthly Hedged to EUR - Dist- DistributionWeight
0.07%
Market value
13.99 M
USD
Explore more ETFs
Frequently Asked Questions
The current price of BIOVF is 37.00 USD — it has increased by 1.13% in the past 24 hours. Watch Swedish Orphan Biovitrum AB stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Swedish Orphan Biovitrum AB stocks are traded under the ticker BIOVF.
We've gathered analysts' opinions on Swedish Orphan Biovitrum AB future price: according to them, BIOVF price has a max estimate of 55.90 USD and a min estimate of 34.43 USD. Watch BIOVF chart and read a more detailed Swedish Orphan Biovitrum AB stock forecast: see what analysts think of Swedish Orphan Biovitrum AB and suggest that you do with its stocks.
BIOVF reached its all-time high on Jan 14, 2026 with the price of 37.00 USD, and its all-time low was 2.44 USD and was reached on Oct 28, 2011. View more price dynamics on BIOVF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
BIOVF stock is 1.12% volatile and has beta coefficient of 1.11. Track Swedish Orphan Biovitrum AB stock price on the chart and check out the list of the most volatile stocks — is Swedish Orphan Biovitrum AB there?
Today Swedish Orphan Biovitrum AB has the market capitalization of 15.72 B, it has decreased by −1.05% over the last week.
Yes, you can track Swedish Orphan Biovitrum AB financials in yearly and quarterly reports right on TradingView.
Swedish Orphan Biovitrum AB is going to release the next earnings report on Apr 28, 2026. Keep track of upcoming events with our Earnings Calendar.
BIOVF earnings for the last quarter are 0.58 USD per share, whereas the estimation was 0.46 USD resulting in a 27.69% surprise. The estimated earnings for the next quarter are 0.42 USD per share. See more details about Swedish Orphan Biovitrum AB earnings.
Swedish Orphan Biovitrum AB revenue for the last quarter amounts to 846.23 M USD, despite the estimated figure of 863.40 M USD. In the next quarter, revenue is expected to reach 794.00 M USD.
BIOVF net income for the last quarter is 201.47 M USD, while the quarter before that showed −306.58 M USD of net income which accounts for 165.71% change. Track more Swedish Orphan Biovitrum AB financial stats to get the full picture.
No, BIOVF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Feb 15, 2026, the company has 1.89 K employees. See our rating of the largest employees — is Swedish Orphan Biovitrum AB on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Swedish Orphan Biovitrum AB EBITDA is 1.96 B USD, and current EBITDA margin is 64.25%. See more stats in Swedish Orphan Biovitrum AB financial statements.
Like other stocks, BIOVF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Swedish Orphan Biovitrum AB stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Swedish Orphan Biovitrum AB technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Swedish Orphan Biovitrum AB stock shows the strong buy signal. See more of Swedish Orphan Biovitrum AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.